TAMPA, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teewinot Life Sciences Corporation (“Teewinot” or the “Company”), a global leader in the biosynthetic production of cGMP cannabinoids and cannabinoid analogs as new chemical entities, today announced Steve Orndorff Ph.D., Chief Operating Officer, will participate on a Biosynthesis panel at Cowen’s 2nd Annual Boston Cannabis Conference being held from November 12-13 2019 at the InterContinental hotel.

Panel Details:
Date:               Wednesday, November 13, 2019
Time:               8:50-9:35 AM ET
Location:         Rose Kennedy Ballroom, InterContinental Boston

For anyone interested in arranging a one-on-one meeting at the event, please contact the bank’s representative or the Company’s investor relations department.

About Teewinot Life Sciences

Teewinot Life Sciences is a global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products. The Company is leveraging a unique integrated biocatalytic and chemical synthesis platform, that allows the production of an unprecedented range of cannabinoids and cannabinoid NCEs from bench to cGMP manufacturing.  This platform supports Teewinot’s drug discovery programs as well as industry partnerships for pharmaceutical and consumer product development. Teewinot is revolutionizing the synthetic cannabinoid space with its cost-effective, commercial scale approach to meet the global growing demand for cannabinoid-based products to address unmet health, wellness, and therapeutic needs.

About CannSynthesis®

CannSynthesis® is the world’s only patent-protected biocatalytic process for the production of rare cannabinoids from bench to cGMP commercial scale. It utilizes a modular approach for bioreactions to produce specific rare cannabinoids at high titer and purity with high efficiency and speed.  The biocatalytic process is complemented with a variety of proprietary chemical transformations to convert the biologically-derived cannabinoids into other rare cannabinoids. Today, this platform allows for Teewinot to deliver the widest and most diverse range of cannabinoids for the growing market demand.    

Forward Looking Statements

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward- looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, ultimate clinical outcomes and benefit of the Company’s products, market acceptance of the Company’s products, intellectual property protection, competitive product offerings, adverse changes in the public perception of cannabis, adverse changes in applicable laws and adverse changes in the application or enforcement of current laws, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com